Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2    source : Www.beyondspringpharma.com    save search
BeyondSpring Announces First Patient Treated in Phase 2 Study with Plinabulin Combined with Nivolumab + Ipilimumab in Patients in 3rd Line Recurrent Small-Cell Lung Cancer Patients Who Failed Checkpoint Inhibitors
Published: 2021-10-21 (Crawled : 11:00) - beyondspringpharma.com
BYSI | $2.29 2.2K twitter stocktwits trandingview |
Health Technology
 | | O: 0.0% H: 0.6% C: -2.27%
phase 2 lung cancer cancer plinabulin nivolumab
Gainers vs Losers
66% 34%

Top 10 Gainers
CZOO | $9.98 100.0% 330K twitter stocktwits trandingview |

AMST | $3.48 74.0% 21M twitter stocktwits trandingview |
Technology Services
BOF | $1.78 52.14% 15M twitter stocktwits trandingview |

SYRA | $1.5 51.23% 1M twitter stocktwits trandingview |
n/a
CSSE 4 | $0.2184 43.4% 36M twitter stocktwits trandingview |
Consumer Services
RILY | $30.325 39.62% 6.8M twitter stocktwits trandingview |
Finance
TROO | $1.41 29.36% 280K twitter stocktwits trandingview |
Manufacturing
MULN | News | $3.445 26.19% 980K twitter stocktwits trandingview |
Information
RBBN 4 | $3.21 24.9% 580K twitter stocktwits trandingview |
Electronic Technology
LICN | $0.6987 24.77% 4.4M twitter stocktwits trandingview |

Your saved searches
Save your searches and get alerts when important news are released.